A review of data involving 944 adults with active diabetic foot ulcers looked at the effects of adding placental-derived products. These products can be cellular, acellular, or matrix-like. The study compared these treatments against standard care or a non-placental control to see if they helped heal wounds.
The results showed that patients who received these placental-derived products had a higher likelihood of complete wound closure at 12 weeks. Specifically, 59 percent of those using the products saw their wounds close, compared to 35.8 percent in the control group. This finding was noted with moderate certainty.
While the results are promising, the study had some limitations. Because different products and settings were involved, the results might not be the same for every patient or every specific product used. You should talk with a healthcare provider to see if these specific treatments are appropriate for your individual care plan.
Common questions
What are placental-derived products?
These are products derived from the placenta that can be cellular, acellular, or matrix-like. In this study, they were used as an addition to standard care to help treat active diabetic foot ulcers. The study found that these products increased the likelihood of wound closure at 12 weeks compared to standard care alone.
How much did these products help heal wounds?
The study found that 59 percent of patients using the placental-derived products achieved complete wound closure at 12 weeks. In comparison, only 35.8 percent of patients in the control group achieved full closure. This indicates a higher likelihood of healing when the products were added to treatment.
Is this treatment the same for everyone?
The study noted that the results might not be the same for every product, patient, or setting. Because there was a variety of products and conditions involved, the specific benefit may vary. You should consult with a medical professional to determine the best treatment for your specific situation.
